Open House Original Drug Discount Agreements 2025-08 – Roxadustat

Summary

The procedure concerns discount agreements for the active substance roxadustat under an Open House arrangement. The contracting authority intends to conclude agreements with all suitable pharmaceutical companies. Individual negotiations are not held; uniform contractual terms apply, and no exclusivity is guaranteed. The contract may last for a maximum of 24 months from 1 April 2025 and ends no later than 31 October 2026. Participation is possible at any time during the contract period. If patent protection or market exclusivity ends earlier, the agreement ends at the end of that month. Only pharmaceutical companies offering or marketing relevant medicines, or credibly intending to do so during the contract period, can receive the participation and contract documents. Precise qualification and compliance requirements must be checked in the official tender documents.